search
Back to results

The Breakfast Study

Primary Purpose

Type 2 Diabetes

Status
Recruiting
Phase
Phase 1
Locations
United States
Study Type
Interventional
Intervention
Breakfast
Sponsored by
University of Michigan
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Type 2 Diabetes focused on measuring Very low carbohydrate diet, Nutrition therapy

Eligibility Criteria

18 Years - 80 Years (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria: HbA1c 8% or higher 18-80 years old The ability to understand verbal and written English Willingness to follow the prescribed diet Able to consent and follow directions Willingness to regularly check blood glucose levels as required Exclusion Criteria: Inability to provide informed consent Pregnant, breastfeeding, or planning for either in the next 6 months or <6 months postpartum Low C-peptide and possible subsequent GAD 65 level that suggests type 1 diabetes, clinical factors that suggest type 1 diabetes (lean, lack of family history, and diabetic ketoacidosis in the past) or a previous diagnosis of type 1 diabetes or latent autoimmune diabetes Cancer, heart failure, or kidney failure Vegan Untreated mental health condition Currently following a very low-carbohydrate diet or breakfasts Thyroid levels out of range Alcoholism Previous bariatric surgery Difficulty chewing or swallowing Dependence on others for food preparation Currently enrolled in another investigative study that might conflict with this research

Sites / Locations

  • University of MichiganRecruiting

Arms of the Study

Arm 1

Arm Type

Experimental

Arm Label

Very low-carbohydrate breakfast

Arm Description

Materials will encourage eating a very low-carbohydrate breakfast (or first meal of the day), with no more than about 5-10 non-fiber (net) grams of carbohydrates each.

Outcomes

Primary Outcome Measures

HbA1c change
percentage of glycosylated hemoglobin

Secondary Outcome Measures

Change in glycemic variability
This will be measured with an Abbott Libre Pro continuous glucose monitoring device on participants' upper arm and the information on the sensor is blinded to participants. The monitoring device will record participants' glucose levels in the interstitial fluid by a glucose oxidase method every 15 minutes, continuously for 14 days at each time point. The glucose variability and the proportion of time spent in the euglycemic (3-7.8 millimoles per litre (mmol/l)) and hyperglycemic (≥ 11.1 mmol/l for at least 15 minutes) states, following previous standards for interstitial glucose concentrations.
Change in percent body weight loss
percent change
Change in Inflammation based on high sensitivity C-reactive protein (hsCRP)
High-sensitivity C-reactive protein will be measured with nephelometric methods utilizing latex particles coated with CRP monoclonal antibodies and standardized against a CRP reference preparation.
Change in low-density lipoproteins (LDL)
This will assess the change in the level reported for this outcome
Change in high-density lipoproteins (HDL)
This will assess the change in the level reported for this outcome
Change in triglycerides
This will assess the change in the level reported for this outcome
Change in systolic blood pressure
Measured with sphygmomanometer, assessed as change in blood pressure (systolic and diastolic blood pressure will both be measured, but systolic blood pressure is the main outcome of interest)
Change in insulin resistance
At baseline and 4 months, we will use fasting insulin and glucose to estimate insulin resistance by calculating Homeostatic Model Assessment-Insulin Resistance (HOMA-IR)

Full Information

First Posted
July 17, 2023
Last Updated
August 2, 2023
Sponsor
University of Michigan
search

1. Study Identification

Unique Protocol Identification Number
NCT05986097
Brief Title
The Breakfast Study
Official Title
The Breakfast Study: A Small Steps, Low-literacy, Breakfast-focused Dietary Self-management Intervention for Adults With Poorly Controlled Type 2 Diabetes
Study Type
Interventional

2. Study Status

Record Verification Date
August 2023
Overall Recruitment Status
Recruiting
Study Start Date
August 2, 2023 (Actual)
Primary Completion Date
October 15, 2025 (Anticipated)
Study Completion Date
October 15, 2025 (Anticipated)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Principal Investigator
Name of the Sponsor
University of Michigan

4. Oversight

Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
Yes

5. Study Description

Brief Summary
The investigators will conduct an acceptability, feasibility, preliminary effectiveness trial of a 4-month, online, very low-carbohydrate breakfast-focused program in 120 adults with type 2 diabetes. The investigators will measure acceptability and feasibility, plus critical efficacy outcomes, such as changes in HbA1c, anti-hyperglycemic medications, glycemic variability, body weight, blood pressure, and lipids.
Detailed Description
More than 15% of U.S. adults with type 2 diabetes have poorly controlled blood gluocse, here defined as a glycated hemoglobin (HbA1c) level of 8.0% or higher. These adults have an elevated health risk of a variety of outcomes, including amputation and mortality from cardiovascular disease and from all causes. Nutrition- focused interventions can be effective for improving glycemic control, reducing anti-hyperglycemic medications, and reducing body weight, all of which are critical outcomes for adults with type 2 diabetes. However, typical nutrition-focused interventions can be burdensome, often requiring complex instructions and a complete overhaul of one's diet. Additionally, adults with poorly controlled type 2 diabetes are more likely to have low literacy levels, which can be a barrier for adherence to complex interventions. Therefore, an effective intervention for adults with poorly controlled diabetes who may have lower health literacy levels is necessary to reduce both HbA1c levels and anti-hyperglycemic medications. Carbohydrate intake has the strongest impact on post-prandial glycemia of any dietary factor, and a very low-carbohydrate diet-due to its ability to improve glycemic control-is now recommended by the American Diabetes Association (ADA) for the treatment of type 2 diabetes. The investigators hypothesize that some of the benefits of a very low-carbohydrate diet may be available to individuals who change only their breakfasts to be very low-carbohydrate, rather than modifying their entire diet. Thus, the investigators will conduct an acceptability, feasibility, preliminary effectiveness trial of a 4-month, online, small- steps, low-literacy, very low-carbohydrate breakfast-focused program in 120 adults with poorly controlled type 2 diabetes. The investigators will measure acceptability and feasibility, plus critical efficacy outcomes, such as changes in HbA1c, anti-hyperglycemic medications, glycemic variability, body weight, blood pressure, and lipids. The investigators will also test whether factors such as sex, health literacy level, and baseline insulin resistance significantly moderate the impact of the intervention on change in HbA1c and change in anti-hyperglycemic medications.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Type 2 Diabetes
Keywords
Very low carbohydrate diet, Nutrition therapy

7. Study Design

Primary Purpose
Treatment
Study Phase
Phase 1, Phase 2
Interventional Study Model
Single Group Assignment
Model Description
All participants will be provided the same intervention.
Masking
None (Open Label)
Masking Description
Blood tests and continuous glucose monitoring are masked.
Allocation
N/A
Enrollment
120 (Anticipated)

8. Arms, Groups, and Interventions

Arm Title
Very low-carbohydrate breakfast
Arm Type
Experimental
Arm Description
Materials will encourage eating a very low-carbohydrate breakfast (or first meal of the day), with no more than about 5-10 non-fiber (net) grams of carbohydrates each.
Intervention Type
Behavioral
Intervention Name(s)
Breakfast
Intervention Description
We will provide participants recipes and information to support this dietary change.
Primary Outcome Measure Information:
Title
HbA1c change
Description
percentage of glycosylated hemoglobin
Time Frame
0 to 4 months
Secondary Outcome Measure Information:
Title
Change in glycemic variability
Description
This will be measured with an Abbott Libre Pro continuous glucose monitoring device on participants' upper arm and the information on the sensor is blinded to participants. The monitoring device will record participants' glucose levels in the interstitial fluid by a glucose oxidase method every 15 minutes, continuously for 14 days at each time point. The glucose variability and the proportion of time spent in the euglycemic (3-7.8 millimoles per litre (mmol/l)) and hyperglycemic (≥ 11.1 mmol/l for at least 15 minutes) states, following previous standards for interstitial glucose concentrations.
Time Frame
0-4 months
Title
Change in percent body weight loss
Description
percent change
Time Frame
0-4 months
Title
Change in Inflammation based on high sensitivity C-reactive protein (hsCRP)
Description
High-sensitivity C-reactive protein will be measured with nephelometric methods utilizing latex particles coated with CRP monoclonal antibodies and standardized against a CRP reference preparation.
Time Frame
0-4 months
Title
Change in low-density lipoproteins (LDL)
Description
This will assess the change in the level reported for this outcome
Time Frame
0 to 4 months
Title
Change in high-density lipoproteins (HDL)
Description
This will assess the change in the level reported for this outcome
Time Frame
0 to 4 months
Title
Change in triglycerides
Description
This will assess the change in the level reported for this outcome
Time Frame
0 to 4 months
Title
Change in systolic blood pressure
Description
Measured with sphygmomanometer, assessed as change in blood pressure (systolic and diastolic blood pressure will both be measured, but systolic blood pressure is the main outcome of interest)
Time Frame
0 to 4 months
Title
Change in insulin resistance
Description
At baseline and 4 months, we will use fasting insulin and glucose to estimate insulin resistance by calculating Homeostatic Model Assessment-Insulin Resistance (HOMA-IR)
Time Frame
0 to 4 months

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Maximum Age & Unit of Time
80 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: HbA1c 8% or higher 18-80 years old The ability to understand verbal and written English Willingness to follow the prescribed diet Able to consent and follow directions Willingness to regularly check blood glucose levels as required Exclusion Criteria: Inability to provide informed consent Pregnant, breastfeeding, or planning for either in the next 6 months or <6 months postpartum Low C-peptide and possible subsequent GAD 65 level that suggests type 1 diabetes, clinical factors that suggest type 1 diabetes (lean, lack of family history, and diabetic ketoacidosis in the past) or a previous diagnosis of type 1 diabetes or latent autoimmune diabetes Cancer, heart failure, or kidney failure Vegan Untreated mental health condition Currently following a very low-carbohydrate diet or breakfasts Thyroid levels out of range Alcoholism Previous bariatric surgery Difficulty chewing or swallowing Dependence on others for food preparation Currently enrolled in another investigative study that might conflict with this research
Facility Information:
Facility Name
University of Michigan
City
Ann Arbor
State/Province
Michigan
ZIP/Postal Code
48109
Country
United States
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Laura Saslow, PhD
Phone
734-763-4995
Email
breakfaststudy@med.umich.edu

12. IPD Sharing Statement

Plan to Share IPD
No

Learn more about this trial

The Breakfast Study

We'll reach out to this number within 24 hrs